ATE259788T1 - Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion - Google Patents
Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktionInfo
- Publication number
- ATE259788T1 ATE259788T1 AT96916599T AT96916599T ATE259788T1 AT E259788 T1 ATE259788 T1 AT E259788T1 AT 96916599 T AT96916599 T AT 96916599T AT 96916599 T AT96916599 T AT 96916599T AT E259788 T1 ATE259788 T1 AT E259788T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- subjects
- ampa receptors
- benzoliperidine
- pyrrolidine
- Prior art date
Links
- 230000009782 synaptic response Effects 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 3
- 102000003678 AMPA Receptors Human genes 0.000 abstract 3
- 108090000078 AMPA Receptors Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000007812 deficiency Effects 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- YXTROGRGRSPWKL-UHFFFAOYSA-N 1-benzoylpiperidine Chemical class C=1C=CC=CC=1C(=O)N1CCCCC1 YXTROGRGRSPWKL-UHFFFAOYSA-N 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000036992 cognitive tasks Effects 0.000 abstract 1
- 230000002964 excitative effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003235 pyrrolidines Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/458,967 US5650409A (en) | 1995-06-02 | 1995-06-02 | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| PCT/US1996/007607 WO1996038414A1 (en) | 1995-06-02 | 1996-05-23 | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE259788T1 true ATE259788T1 (de) | 2004-03-15 |
Family
ID=23822840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96916599T ATE259788T1 (de) | 1995-06-02 | 1996-05-23 | Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5650409A (de) |
| EP (1) | EP0839134B1 (de) |
| JP (1) | JP3464800B2 (de) |
| KR (2) | KR100621499B1 (de) |
| AT (1) | ATE259788T1 (de) |
| AU (1) | AU708715B2 (de) |
| CA (1) | CA2222976C (de) |
| DE (1) | DE69631588T2 (de) |
| DK (1) | DK0839134T3 (de) |
| ES (1) | ES2216048T3 (de) |
| PL (1) | PL187895B1 (de) |
| PT (1) | PT839134E (de) |
| WO (1) | WO1996038414A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| AU721936B2 (en) * | 1996-04-03 | 2000-07-20 | Regents Of The University Of California, The | Benzoxazines for enhancing synaptic response |
| AU714477B2 (en) * | 1996-04-19 | 2000-01-06 | Regents Of The University Of California, The | Treatment of mood/affective disorders by glutamatergic upmodulators |
| AU4416197A (en) * | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US6329368B1 (en) * | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| DK1026950T3 (da) * | 1997-10-27 | 2006-06-26 | Univ California | Behandling af skizofreni med ampakiner og neuroleptika |
| US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| US6943159B1 (en) | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
| US6124278A (en) * | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
| TWI232863B (en) * | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
| KR100864267B1 (ko) * | 2001-06-14 | 2008-10-20 | 엔.브이.오가논 | ＡＭＰＡ 수용체의 양성 조절제로서의(피리도/티에노)-[ｆ]-옥사제핀-5-온 유도체 |
| WO2003045315A2 (en) * | 2001-11-26 | 2003-06-05 | Cortex Pharmaceuticals, Inc. | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| EP1592464A4 (de) | 2003-01-13 | 2011-03-09 | Cortex Pharma Inc | Verfahren zur behandlung von kognitivem verfall aufgrund von schlafmangel und stress |
| US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| CN101626686A (zh) * | 2007-01-03 | 2010-01-13 | 科泰克斯药品公司 | 用于提高谷氨酸性突触反应的3-取代基-1,2,3-苯并三嗪酮类化合物 |
| AP2502A (en) * | 2007-01-03 | 2012-10-23 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| JP5526018B2 (ja) * | 2007-03-21 | 2014-06-18 | エミスフェアー・テクノロジーズ・インク | アリルオキシおよびアルキルオキシ安息香酸送達薬剤 |
| WO2008143963A1 (en) * | 2007-05-17 | 2008-11-27 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
| US8263591B2 (en) * | 2007-08-10 | 2012-09-11 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
| US8119632B2 (en) | 2007-08-10 | 2012-02-21 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
| US20110218190A1 (en) * | 2008-11-10 | 2011-09-08 | The Regents Of The University Of California | Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction |
| WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| EP2801377B1 (de) | 2011-03-04 | 2019-08-07 | The Regents of The University of California | Hydrogel enthaltend Zellen zur lokalen Freisetzung von Wachstumsfaktoren zur Rückgewinnung der Bewegungsfähigkeit nach einem Schlaganfall |
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| US20150011554A1 (en) | 2013-06-13 | 2015-01-08 | Veroscience Llc | Compositions and Methods for Treating Metabolic Disorders |
| GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
| GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
| EP3436021A4 (de) | 2016-03-29 | 2019-11-06 | RespireRx Pharmaceuticals Inc. | Zusammensetzungen und verfahren zur behandlung von aufmerksamkeitsdefizitstörungen |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3406177A (en) * | 1965-05-12 | 1968-10-15 | Johnson & Son Inc S C | N-(meta-toluyl)-methylpiperidines |
| US3463855A (en) * | 1965-05-12 | 1969-08-26 | Johnson & Son Inc S C | Insect repellent compositions of n-(meta-toluyl)-methyl piperidines |
| JPH01207284A (ja) * | 1987-10-06 | 1989-08-21 | Takeda Chem Ind Ltd | アミド化合物 |
| EP1367056A1 (de) * | 1992-07-24 | 2003-12-03 | The Regents Of The University Of California | Arzneimittel die den durch AMPA Rezeptoren vermittelten synaptischen Respons erhöhen |
-
1995
- 1995-06-02 US US08/458,967 patent/US5650409A/en not_active Expired - Fee Related
-
1996
- 1996-05-23 ES ES96916599T patent/ES2216048T3/es not_active Expired - Lifetime
- 1996-05-23 AT AT96916599T patent/ATE259788T1/de active
- 1996-05-23 PL PL96323667A patent/PL187895B1/pl not_active IP Right Cessation
- 1996-05-23 EP EP96916599A patent/EP0839134B1/de not_active Expired - Lifetime
- 1996-05-23 DK DK96916599T patent/DK0839134T3/da active
- 1996-05-23 KR KR1020037016547A patent/KR100621499B1/ko not_active Expired - Fee Related
- 1996-05-23 KR KR1019970708728A patent/KR100444539B1/ko not_active Expired - Fee Related
- 1996-05-23 AU AU59293/96A patent/AU708715B2/en not_active Ceased
- 1996-05-23 CA CA002222976A patent/CA2222976C/en not_active Expired - Fee Related
- 1996-05-23 DE DE69631588T patent/DE69631588T2/de not_active Expired - Lifetime
- 1996-05-23 JP JP53656896A patent/JP3464800B2/ja not_active Expired - Fee Related
- 1996-05-23 PT PT96916599T patent/PT839134E/pt unknown
- 1996-05-23 WO PCT/US1996/007607 patent/WO1996038414A1/en not_active Ceased
-
1997
- 1997-03-21 US US08/822,027 patent/US5783587A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990022249A (ko) | 1999-03-25 |
| DK0839134T3 (da) | 2004-08-16 |
| WO1996038414A1 (en) | 1996-12-05 |
| DE69631588D1 (de) | 2004-03-25 |
| US5783587A (en) | 1998-07-21 |
| PL323667A1 (en) | 1998-04-14 |
| CA2222976A1 (en) | 1996-12-05 |
| PL187895B1 (pl) | 2004-10-29 |
| AU708715B2 (en) | 1999-08-12 |
| EP0839134A1 (de) | 1998-05-06 |
| JP2001503012A (ja) | 2001-03-06 |
| JP3464800B2 (ja) | 2003-11-10 |
| EP0839134B1 (de) | 2004-02-18 |
| KR100444539B1 (ko) | 2004-10-14 |
| AU5929396A (en) | 1996-12-18 |
| ES2216048T3 (es) | 2004-10-16 |
| US5650409A (en) | 1997-07-22 |
| KR20040004716A (ko) | 2004-01-13 |
| DE69631588T2 (de) | 2004-12-16 |
| KR100621499B1 (ko) | 2006-09-14 |
| CA2222976C (en) | 2001-04-24 |
| PT839134E (pt) | 2004-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE259788T1 (de) | Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion | |
| ATE226206T1 (de) | Benzoxazine zur erhöhung der synaptischen reaktionen | |
| CA2138533A1 (en) | Drugs that enhance synaptic responses mediated by ampa receptors | |
| Altenmüller | How many music centers are in the brain? | |
| ATE194593T1 (de) | 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten | |
| ATE261306T1 (de) | Benzoxazin-derivate zur erhöhung der synaptischen reaktion | |
| DE69834590D1 (de) | Benzofurazanderivate und deren verwendung zur verbesserung glutaminerger synaptischer antworten | |
| NO306779B1 (no) | Naftalamider, anvendelse derav og farmasöytisk preparat | |
| SE9102688L (sv) | Foerfarande foer behandling av avfallsvatten med avseende paa organiska foeroreningar med organiskt modifierade smektitlerakompositioner | |
| ATE247472T1 (de) | Acylbenzoxazine zur erhöhung der synaptischen reaktion(en) | |
| EA200400584A1 (ru) | Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов | |
| Ding et al. | The role of inhibitory neurons in novelty sound detection in regular and random statistical contexts | |
| AU4654097A (en) | Rdgb-proteins | |
| DE69628884D1 (de) | Vorrichtung zur Sprachwiedergabe von langen Sprachäusserungen mit verringertem Speicherbedarf | |
| Rotondo et al. | PRECISE MEMORY IS PREDICTED BY LEARNING-INDUCED SENSORY SYSTEM NEUROPHYSIOLOGICAL PLASTICITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0839134 Country of ref document: EP |